Agios Pharmaceuticals Reports $44.7M Revenue and $100.7M Net Loss for Q2 2026

Agios Pharmaceuticals, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company generated total revenues of $44.7 million for the quarter, a substantial increase from $12.5 million in the same period last year. This growth was primarily driven by product revenue from its recently launched drug AQVESME™, which accounted for $40.9 million in U.S. sales. For the first half of 2026, total revenue reached $65.5 million, compared to $21.2 million in the first half of 2025, reflecting a similar trend of increased sales from both AQVESME™ and PYRUKYND®.

Despite the revenue growth, Agios reported a net loss of $100.7 million for the second quarter of 2026, a slight improvement from a net loss of $112.0 million in the same quarter of 2025. For the six-month period, the net loss was $199.8 million, down from $201.3 million year-over-year. The company attributed the ongoing losses to increased operating expenses, which rose to $155.3 million in the second quarter, up from $139.5 million in the prior year, driven by higher research and development costs and increased selling, general, and administrative expenses associated with the launch of AQVESME™.

In terms of strategic developments, Agios entered into a license agreement with Oscotec in June 2026, acquiring rights to develop and commercialize cevidoplenib, a potential treatment for immune thrombocytopenia (ITP). This agreement included a $25 million upfront payment, which was recorded as research and development expense. The company is also advancing its clinical pipeline, with ongoing trials for mitapivat, including a phase 3 trial for sickle cell disease, and has filed for regulatory approval in multiple regions.

Operationally, Agios reported a cash and marketable securities balance of $1.0 billion as of June 30, 2026, providing a solid foundation for its ongoing operations. The company continues to focus on expanding its product offerings and market presence, with plans to commercialize AQVESME™ and PYRUKYND® in various international markets. Looking ahead, Agios expects to incur significant expenses as it continues to develop its product candidates and expand its commercialization efforts, while also navigating the challenges of maintaining profitability in a competitive biopharmaceutical landscape.